Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Multiple Ascending Dose Study of Elotuzumab With Lenalidomide and Low-dose Dexamethasone in Relapsed or Refractory Multiple Myeloma (Japan)
jRCT2080221323Phase 1
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elotuzumab in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoints: Primary safety and tolerability of elotuzumab in combination with lenalidomide and low-dose dexamethasone and Pharmacokinetics of elotuzumab.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080221323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221323.